Peptide Dosage Chart: Research-Reported Reference Figures
Researchers working with multiple peptide compounds often need a consolidated reference covering typical study doses, administration routes, and cycle lengths reported in the preclinical and clinical literature. This page compiles those figures into a single chart. All values are drawn from published animal studies and, where available, limited human trials. They are not dosing recommendations and should not be interpreted as such.
For detailed context on any individual compound, the dedicated protocol pages at protocols and the compound-specific blog guides go much deeper than this chart can. Use this page as a quick orientation, not as a standalone guide.
How the figures are organized
The table below lists each compound alongside four data points derived from the research literature: the range of quantities used in studies, how frequently doses were administered, the primary route of administration reported, and the typical study duration. Where studies have used multiple routes or frequencies, the most commonly reported approach is shown. The "Route" column uses standard abbreviations: SC for subcutaneous, IV for intravenous, IP for intraperitoneal, and oral for administered by mouth.
Peptide dosage reference chart
All figures below are research-reported quantities from preclinical and limited clinical studies. They are not dosing advice. Research use only.
| Peptide | Study Quantity Range | Frequency | Route | Typical Study Duration |
|---|---|---|---|---|
| BPC-157 | 1-10 mcg/kg (animal); 250-500 mcg (translational) | Once daily | SC or oral | 4-12 weeks |
| TB-500 (Thymosin Beta-4) | 2-5 mg per administration | 1-2x per week (loading); 1x per week (maintenance) | SC | 4-6 weeks loading, then ongoing |
| CJC-1295 (no DAC) | 100-300 mcg per injection | 2-3x per week | SC | 8-12 weeks |
| CJC-1295 (with DAC) | 1-2 mg per injection | Once per week | SC | 8-12 weeks |
| Ipamorelin | 200-300 mcg per injection | 2-3x per day (pulsatile) | SC | 8-12 weeks |
| IGF-1 LR3 | 40-100 mcg per day | Once daily | SC | 4-6 weeks; cycle breaks advised in research |
| Tesamorelin | 1-2 mg per day | Once daily | SC | 26-52 weeks (clinical trials for lipodystrophy) |
| MOTS-c | 5-15 mg per week | 1-3x per week | SC or IP (animal studies) | 4-8 weeks |
| SS-31 (Elamipretide) | 1-20 mg/kg (animal); 0.05-0.25 mg/kg (Phase II human) | Once daily | SC or IV | Variable; up to 28 days in human trials |
| DSIP (Delta Sleep-Inducing Peptide) | 25-100 mcg per injection | Every other day to daily | SC or IV | 1-3 weeks (short course protocols) |
Reading the chart correctly
Several details in the table require context before the figures are meaningful in a research setting.
Animal versus translational quantities
Most peptide research originates in rodent models. Direct conversion of animal doses to human-equivalent quantities is not straightforward and involves body surface area scaling. For BPC-157, for example, the 1-10 mcg/kg animal dose does not translate directly to the 250-500 mcg figure sometimes referenced in translational discussions. Researchers should consult the primary literature for the specific conversion method used in any study they reference.
CJC-1295 formulation matters
The two CJC-1295 variants listed differ significantly in half-life and dosing interval. The no-DAC (Drug Affinity Complex) version has a short half-life, requiring more frequent administration and making it suitable for pulsatile growth hormone release protocols. The DAC version binds to albumin and stays active much longer, which is why once-weekly administration appears in the literature. These are distinct compounds and should not be treated as interchangeable. See the CJC-1295 protocol page for a full breakdown.
Ipamorelin pulse timing
Ipamorelin is a selective growth hormone secretagogue studied for its ability to produce clean, pulsatile GH release without significantly raising cortisol or prolactin. Research protocols pair it with a GHRH such as CJC-1295, which is why CJC-1295 and ipamorelin combination dosage is a common search topic. The timing of each pulse relative to sleep and fasting windows varies across studies. See the ipamorelin protocol for study-specific context.
IGF-1 LR3 cycle length
IGF-1 LR3 has a longer half-life than native IGF-1 (roughly 20-30 hours versus minutes), which is why research protocols in the literature typically keep cycles short. Extended exposure has raised questions about receptor desensitization and other downstream effects. The IGF-1 LR3 protocol covers the specific study contexts behind those precautions.
Tesamorelin and its approved context
Tesamorelin is unique among the peptides in this chart in that it holds FDA approval (as Egrifta) for HIV-associated lipodystrophy. The clinical trial doses of 1-2 mg daily and study durations of 26-52 weeks come from that specific patient context. Research applications outside that approved indication remain investigational. The tesamorelin vs ipamorelin comparison explains how researchers distinguish between these two GH-axis peptides.
Reconstitution before you can use the chart
Raw lyophilized peptide powder must be reconstituted with bacteriostatic water (BAC water) before quantities can be drawn and measured accurately. The concentration you prepare determines what volume corresponds to any given quantity from the chart above. For example, if you dissolve 5 mg of a peptide into 2 mL of BAC water, each 0.1 mL (100 units on a standard insulin syringe) contains 250 mcg. Getting this calculation right is a prerequisite to working meaningfully with any dosage chart. The peptide reconstitution guide walks through the full process, and the peptide calculator handles the arithmetic automatically.
Using the chart alongside protocol pages
This chart gives starting coordinates, not complete protocols. Protocols include information on carrier solutions, storage requirements, cycle timing, wash-out periods, and the rationale behind each parameter. Before using any figure from the table above as a basis for research, cross-reference it with the appropriate protocol:
- BPC-157 full protocol
- TB-500 full protocol
- CJC-1295 full protocol
- Ipamorelin full protocol
- IGF-1 LR3 full protocol
The protocols index lists every compound covered on this site.